Cargando…

Addressing missing data in randomized clinical trials: A causal inference perspective

BACKGROUND: The importance of randomization in clinical trials has long been acknowledged for avoiding selection bias. Yet, bias concerns re-emerge with selective attrition. This study takes a causal inference perspective in addressing distinct scenarios of missing outcome data (MCAR, MAR and MNAR)....

Descripción completa

Detalles Bibliográficos
Autores principales: Cornelisz, Ilja, Cuijpers, Pim, Donker, Tara, van Klaveren, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337281/
https://www.ncbi.nlm.nih.gov/pubmed/32628678
http://dx.doi.org/10.1371/journal.pone.0234349
_version_ 1783554476782649344
author Cornelisz, Ilja
Cuijpers, Pim
Donker, Tara
van Klaveren, Chris
author_facet Cornelisz, Ilja
Cuijpers, Pim
Donker, Tara
van Klaveren, Chris
author_sort Cornelisz, Ilja
collection PubMed
description BACKGROUND: The importance of randomization in clinical trials has long been acknowledged for avoiding selection bias. Yet, bias concerns re-emerge with selective attrition. This study takes a causal inference perspective in addressing distinct scenarios of missing outcome data (MCAR, MAR and MNAR). METHODS: This study adopts a causal inference perspective in providing an overview of empirical strategies to estimate the average treatment effect, improve precision of the estimator, and to test whether the underlying identifying assumptions hold. We propose to use Random Forest Lee Bounds (RFLB) to address selective attrition and to obtain more precise average treatment effect intervals. RESULTS: When assuming MCAR or MAR, the often untenable identifying assumptions with respect to causal inference can hardly be verified empirically. Instead, missing outcome data in clinical trials should be considered as potentially non-random unobserved events (i.e. MNAR). Using simulated attrition data, we show how average treatment effect intervals can be tightened considerably using RFLB, by exploiting both continuous and discrete attrition predictor variables. CONCLUSIONS: Bounding approaches should be used to acknowledge selective attrition in randomized clinical trials in acknowledging the resulting uncertainty with respect to causal inference. As such, Random Forest Lee Bounds estimates are more informative than point estimates obtained assuming MCAR or MAR.
format Online
Article
Text
id pubmed-7337281
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-73372812020-07-16 Addressing missing data in randomized clinical trials: A causal inference perspective Cornelisz, Ilja Cuijpers, Pim Donker, Tara van Klaveren, Chris PLoS One Research Article BACKGROUND: The importance of randomization in clinical trials has long been acknowledged for avoiding selection bias. Yet, bias concerns re-emerge with selective attrition. This study takes a causal inference perspective in addressing distinct scenarios of missing outcome data (MCAR, MAR and MNAR). METHODS: This study adopts a causal inference perspective in providing an overview of empirical strategies to estimate the average treatment effect, improve precision of the estimator, and to test whether the underlying identifying assumptions hold. We propose to use Random Forest Lee Bounds (RFLB) to address selective attrition and to obtain more precise average treatment effect intervals. RESULTS: When assuming MCAR or MAR, the often untenable identifying assumptions with respect to causal inference can hardly be verified empirically. Instead, missing outcome data in clinical trials should be considered as potentially non-random unobserved events (i.e. MNAR). Using simulated attrition data, we show how average treatment effect intervals can be tightened considerably using RFLB, by exploiting both continuous and discrete attrition predictor variables. CONCLUSIONS: Bounding approaches should be used to acknowledge selective attrition in randomized clinical trials in acknowledging the resulting uncertainty with respect to causal inference. As such, Random Forest Lee Bounds estimates are more informative than point estimates obtained assuming MCAR or MAR. Public Library of Science 2020-07-06 /pmc/articles/PMC7337281/ /pubmed/32628678 http://dx.doi.org/10.1371/journal.pone.0234349 Text en © 2020 Cornelisz et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Cornelisz, Ilja
Cuijpers, Pim
Donker, Tara
van Klaveren, Chris
Addressing missing data in randomized clinical trials: A causal inference perspective
title Addressing missing data in randomized clinical trials: A causal inference perspective
title_full Addressing missing data in randomized clinical trials: A causal inference perspective
title_fullStr Addressing missing data in randomized clinical trials: A causal inference perspective
title_full_unstemmed Addressing missing data in randomized clinical trials: A causal inference perspective
title_short Addressing missing data in randomized clinical trials: A causal inference perspective
title_sort addressing missing data in randomized clinical trials: a causal inference perspective
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337281/
https://www.ncbi.nlm.nih.gov/pubmed/32628678
http://dx.doi.org/10.1371/journal.pone.0234349
work_keys_str_mv AT corneliszilja addressingmissingdatainrandomizedclinicaltrialsacausalinferenceperspective
AT cuijperspim addressingmissingdatainrandomizedclinicaltrialsacausalinferenceperspective
AT donkertara addressingmissingdatainrandomizedclinicaltrialsacausalinferenceperspective
AT vanklaverenchris addressingmissingdatainrandomizedclinicaltrialsacausalinferenceperspective